Seres Therapeutics, Inc. develops live biotherapeutic products and microbiome-based therapies for inflammatory, immune, infectious and gastrointestinal diseases. Company updates commonly address pipeline programs such as SER-155 for immune checkpoint inhibitor-related enterocolitis and prevention of bloodstream infections in allogeneic hematopoietic stem cell transplant patients, SER-603 for inflammatory bowel disease, and SER-428 for antimicrobial resistance and serious infections.
Recurring announcements include financial results, operational updates, research publications, scientific conference presentations, biomarker and microbiome-mechanism data, collaborations, financing and partnership activity, cost-control measures, and governance changes.
Seres Therapeutics announced a memorandum of understanding with Nestlé Health Science to sell its VOWST assets, which include intellectual property rights. The deal is expected to provide Seres with capital infusions and an upfront payment, allowing the company to retire its debt and extend its cash runway into Q4 2025. The transaction, anticipated to complete within 90 days, is subject to shareholder approval and other conditions. Seres will shift focus to advancing SER-155 and other microbiome therapeutics. This agreement builds on a previous license agreement with Nestlé and recent FDA approval for VOWST to treat recurrent CDI. Seres expects this deal to strengthen its balance sheet and enable progress in its therapeutic programs.
Seres Therapeutics, Inc. (Nasdaq: MCRB) reported first quarter 2024 financial results highlighting net sales of $10.1 million for VOWST, accelerating sales growth since launch, and progress in clinical trials. The company aims to expand its product franchise into additional patient populations and secure more capital for pipeline development.
Seres Therapeutics, Inc. announced the grant of equity awards to two new employees under the Inducement Plan. The grants consist of stock options and RSUs, totaling 9,367 shares of common stock. These awards are subject to specific vesting schedules and were granted under Nasdaq Listing Rule 5635(c)(4).
Seres Therapeutics, Inc. (Nasdaq: MCRB) will discuss their first quarter 2024 financial results and provide business updates on May 8, 2024. The conference call and webcast are scheduled for 8:30 a.m. ET. Investors can access the call by dialing the provided numbers or by visiting the Seres website. A replay will be available on the website for 21 days.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.